25 filings · most recent first
LLY 8-K Filings
Eli Lilly Completes Offering Of Multiple Series Of Notes
Eli Lilly Shareholders Elect Directors At 2026 Annual Meeting
Eli Lilly Announces Q1 2026 Financial Results
Eli Lilly Announces Strong Q4 2025 Results And 2026 Guidance
Eli Lilly Announces Issuance Of Multiple Debt Notes
Eli Lilly Announces New Note Issuance
Eli Lilly Issues Bonds Worth 496 Billion
Eli Lilly Announces Underwriting Agreement For Note Issuance
Eli Lilly Appoints Dr Carolyn R Bertozzi To Board Of Directors
Eli Lilly Reports Strong Q3 2025 Results With 54 Revenue Growth And Raised
Eli Lilly Announces Strong Second Quarter 2025 Results And Raises Fullyear
Eli Lilly Shareholders Approve Director Elections And Executive Compensation At
Eli Lilly Q1 2025 Financial Results Significant Revenue Growth And Pipeline
Eli Lilly Reports Strong Q4 2024 Financial Results And Provides 2025 Guidance
Eli Lilly Updates 2024 Revenue Guidance And Announces 2025 Outlook
Eli Lilly Board Welcomes New Director And Announces Resignation
Eli Lilly Reports Q3 2024 Financial Results With Strong Revenue Growth
Eli Lilly Appoints Lucas Montarce As New Cfo
Eli Lilly Announces Retirement Of Board Member Dr Marschall S Runge
Eli Lilly Q2 2024 Significant Revenue Growth And Eps Increase
Eli Lilly Announces Cfo Resignation And Interim Replacement
Eli Lilly Cfo Anat Ashkenazi Resigns To Pursue New Career
Eli Lilly Shareholders Approve Director Elections And Executive Compensation At
Eli Lilly Reports Q1 2024 Financial Results And Raises Fullyear Revenue Guidance
Eli Lilly Reports Strong Q4 2023 Financial Results And 2024 Guidance